Future-proofing your serialisation solution

In order to tackle the growing problem of counterfeit medicines, the EU has introduced the European Falsified Medicines Directive due to come into force in February 2019. By this time, three quarters of the world’s prescription medicines will fall under track and trace legislation aimed at preserving supply chain integrity. However, many companies are anticipating later legislation that will build on serialisation, such as aggregation, rather than simply focusing on meeting compliance.

In this article with European Pharmaceutical Manufacturer, Colin Newbould, Director of Regulatory Affairs and QP services, discusses the challenges of track and trace legislation in light of the upcoming deadline, and likely changes to regulation in the future.

“integrating aggregation into your approach ahead of schedule will allow you to realise the full benefits of track and trace”

For full article see: https://bit.ly/2NxfzQN

Comments are currently closed.